PREOS NPS Allelix/Nycomed

Current Opinion in Investigational Drugs

Volumn 6, Issue 10, 2005, Pages 1057-1066

  White, Helen ^a   Ahmad, Aftab ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALX 1 11; CALCIUM; ESTRADIOL; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PREOTACT; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; VITAMIN D;

BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE MINERAL; BONE REMODELING; BONE TUMOR; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIET SUPPLEMENTATION; DIZZINESS; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRACTURE; HEADACHE; HEART INFARCTION; HUMAN; HYPERCALCEMIA; INJECTION SITE REACTION; LIMB PAIN; NAUSEA; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PHARMACODYNAMICS; REVIEW; RISK ASSESSMENT; STROKE; STRUCTURE ANALYSIS; VOMITING;

ANIMALS; BONE DENSITY; CLINICAL TRIALS; DRUG INDUSTRY; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 27544461867     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. 121991 Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Wronski TJ, Yen CF, Qi H, Dann LM ENDOCRINOLOGY 1993 132 2 823-831
2. 176367 Allelix acquires full commercial rights to osteoporosis therapeutic and announces Canadian approval to begin phase II trials. Allelix Biopharmaceuticals PRESS RELEASE 1995 April 04
3. 229654 Annual report 1996 - Allelix Biopharma. Allelix Biopharmaceuticals Inc ANNUAL REPORT 1996 December 31
4. 258536 Structure of human parathyroid hormone(1-34) in the presence of solvents and micelles. Strickland LA, Bozzato RP, Kronis KA BIOCHEMISTRY 1993 32 23 6050-6057
5. 258537 Conformation of parathyroid hormone: Time-resolved fluorescence studies. Willis KJ, Szabo AG BIOCHEMISTRY 1992 31 37 8924-8931
6. 299473 Allelix reacquires its phase II osteoporosis drug from Astra/discussions underway to sign new partner. Allelix Biopharmaceuticals PRESS RELEASE 1998 September 24
7. 302408 Allelix announces positive phase II results on ALX1-11. Allelix Biopharmaceuticals Inc PRESS RELEASE 1998 October 23
8. 308116 Allelix drug increases bone density and content in women with osteoporosis; ALX1-11 rapidly and significantly increased bone mass in advanced osteoporosis. Allelix Blopharmaceuticals Inc PRESS RELEASE 1998 December 03
9. 310387 Pharmaceutical & Biotechnology Bulletin. MERRILL LYNCH CAPITAL MARKETS 1998 December 15
10. 330479 Allelix Biopharmaceuticals PRESS RELEASE 1999 May 13
11. 330483 The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR ENDOCRINOLOGY 1993 132 4 1577-1583
12. 353779 NPS reports positive ALX1-11 results from space shuttle experiments. NPS Allelix Inc PRESS RELEASE 2000 January 28
13. 355776 NPS Pharmaceuticals announces phase III osteoporosis trial. NPS Pharmaceuticals Inc PRESS RELEASE 2000 February 15
14. 358429 Global Healthcare Bulletin. MERRILL LYNCH CAPITAL MARKETS 2000 February 15
15. 370526 Lilly details its late stage pipeline to Wall Street - company also outlines its compelling growth strategy. Eli Lilly & Co PRESS RELEASE 2000 June 12
16. 407104 Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): A novel camptothecin analog. Royce ME, Hoff PM, Dumas P, Lassere Y, Lee JJ, Coyle J, Ducharme MP, De Jager R, Pazdur R J CLIN ONCOL 2001 19 5 1493-1500
17. 408551 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH NEW ENGL J MED 2001 344 19 1434-1441
18. 464651 Investor relations: NPS presentation - Bear Stearns 15th Annual Healthcare Conference, New York, NY, USA. NPS Pharmaceuticals Inc COMPANY PRESENTATION 2002 September 17
19. 465474 NPS completes PREOS study enrollment. NPS Pharmaceuticals Inc PRESS RELEASE 2002 September 30
20. 467310 Risks and benefits of estrogen plus progestin in healthy menopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J J AM MED ASSOC 2002 288 3 321-333
21. 476531 NPS compound, PREOS, tested in space. NPS Pharmaceuticals Inc PRESS RELEASE 2003 January 16
22. 505583 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ N ENGL J MED 2003 349 13 1207-1215
23. 514215 NPS reports positive results in PREOS carcinogenicity study. NPS Pharmaceuticals Inc PRESS RELEASE 2003 November 20
24. 518350 ALX III: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84). DRUGS R&D 2003 4 4 231-235
25. 518352 Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats. Samnegard E, Akhter M, Recker RR BONE 2001 28 4 414-422
26. 518353 Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH. Iwaniec UT, Samnegard E, Cullen DM, Kimmel DB BONE 2001 29 4 352-360
27. 518354 Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats. Samnegard E, Iwaniec UT, Cullen DM, Kimmel DB, Recker RR BONE 2001 28 3 251-260
28. 529786 NPS's PREOS meets endpoint in phase III osteoporosis study. NPS Pharmaceuticals Inc PRESS RELEASE 2004 March 30
29. 531786 Treatment of postmenopausal osteoporosis. Delmas PD LANCET 2002 359 9322 2018-2026
30. 533968 NPS Pharmaceuticals and Nycomed announce US $90+ million PREOS marketing agreement for Europe. NPS Pharmaceuticals Inc PRESS RELEASE 2004 April 21
31. 562295 NPS's PREOS continues to show efficacy in osteoporosis trial. NPS Pharmaceuticals PRESS RELEASE 2004 October 04
32. 563046 Lilly's Forteo prevents future fractures in fracture prone osteoporotics. Eli Lilly & Co PRESS RELEASE 2004 October 07
33. 565981 NPS Pharmaceuticals presents additional TOP study data at ACR. NPS Pharmaceuticals Inc PRESS RELEASE 2004 October 21
34. 592348 EMEA accepts MAA for NPS and Nycomed's osteoporosis drug. NPS Pharmaceuticals Inc PRESS RELEASE 2005 March 31
35. 593991 NPS Pharmaceuticals reports first quarter 2005 operating results. NPS Pharmaceuticals Inc PRESS RELEASE 2005 May 10
36. 600523 New TOP study data analyses of PREOS show improved bone microarchitecture and reduction in vertebral fractures in postmenopausal osteoporotic patients. NPS Pharmaceuticals Inc PRESS RELEASE 2005 April 07
37. 611654 NPS's parathyroid hormone NDA accepted for FDA review. NPS Pharmaceuticals Inc PRESS RELEASE 2005 July 11
38. 613850 In vivo distribution of parathyroid hormone receptors in bone: Evidence that a predominant osseous target cell is not the mature osteoblast. Rouleau MF, Mitchell J, Goltzman D ENDOCRINOLOGY 1988 123 1 187-191
39. 613858 The parathyroid hormone circadian rhythm is truly endogenous - a general clinical research center study. J CLIN ENDOCRINOL METAB 1997 82 1 281-286
40. 613859 Alteration of the circadian rhythm of intact parathyroid hormone and serum phosphate in women with established postmenopausal osteoporosis. Fraser WD, Logue FC, Christie JP, Gallacher SJ, Cameron D, O'Reilly DS, Beastall GH, Boyle IT OSTEOPOROS INT 1998 8 2 121-126
41. 613861 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F LANCET 1997 350 9077 550-555
42. 613862 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicenter trial. Reeve J, Meunier PJ, Parsons JA, Bernal M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D et al BMJ 1980 280 6228 1340-1344
43. 613864 Parathyroid hormone: Chemistry, biosynthesis, and mode of action. Potts JT, Kronenberg, HM, Rosenblatt M ADV PROT CHEM 1982 35 323-396
44. 613866 Receptors for the carboxyl-terminal region of PTH (1-84) are highly expressed in osteocytic cells. Divieti P, Inomata N, Chapin K, Singh R, Juppner H, Bringhurst FR ENDOCRINOLOGY 2001 1 42 916-925
45. 613868 Carboxyl-terminal parathyroid hormone peptide (53-84) elevates alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells. Sutherland MK, Rao LG, Wylie JN, Gupta A, Ly H, Sodek J, Murray TM J BONE MINERAL RES 1994 9 4 453-458
46. 613872 Single-dose subcutaneous administration of recombinant human parathyroid hormone (rhPTH(1-84)) in healthy postmenopausal volunteers. Schwietert HR, Groen EW, Sollie FA, Jonkman JH CLIN PHARMACOL THER 1997 61 3 360-376
47. 613876 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodelling in patients with osteoporosis. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ J CLIN INVEST 1997 100 6 1475-1480
48. 614154 Osteoporosis: Underrated, underdiagnosed and undertreated. Nguyen TV, Center JR, Eisman JA MED J AUST 2004 180 5 S18-S22
49. 615158 Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Gunness-Hey M, Hock JM BONE 1989 10 6 447-452
50. 617109 Parathyroid hormone and teraparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwell E, Yuen CK ENDOCR REV 2005 26 5 688-703
51. 617267 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators N ENGL J MED 2005 353 6 555-565
52. 618896 Optimal calcium intake. Heaney RP J AM MED ASSOC 1994 272 24 1942-1948
53. 618899 Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ BMJ 1994 308 6936 1801-1802
54. 621263 NPSP: Plans to expand PREOS NDA data. Wang E SMITH BARNEY CITIGROUP (MORNING MEETING NOTES) 2004 November 30